Table 2. Adverse effects across trials [12, 23].
| Trial name | Grade ≥3 AEs (%) | Notable specific AEs |
|---|---|---|
| CHRYSALIS (NCT02609776) | 35% (Amivantamab monotherapy) | Rash (86% all-grade, 3% grade ≥3), IRRs (66%, mostly grade 1–2), paronychia (45%) |
| PAPILLON (NCT04538664) | Ami + Chemo: 75% versus Chemo: 54% | Neutropenia (59% all grade, 33% grade ≥3), rash (54% all-grade, 11 grade ≥3), paronychia (56%) |
AEs = adverse effects; Ami = amivantamab; Chemo = chemotherapy. Original table